Zelira Therapeutics aims to extend its cannabinoid medication footprint
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) global CEO Oludare Odumosu updates Proactive on the company’s progress with its proprietary revenue-generating products and its pipeline of candidates undergoing clinical development to enter global markets. Odumosu discusses how Zelira is addressing global unmet medical needs in the areas of insomnia and autism through cannabinoid medications. Its goal is to clinically validate these medications, bring them to regulatory approval and then to market.i
ZLD Price at posting:
$1.01 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)